Physician profile
Salima Dewani
NPI 1528520947
$1,185.30
in general payments reported to CMS, 2019-2025
19 companies · $530 in 2025
The $530 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $351 · 2023: $50.69 · 2024: $152 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $201.49 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.33 | 2022-2025 | Relistor |
| Medtronic, INC. | $139.51 | 2021-2022 | |
| Forte Bio-Pharma LLC | $94.03 | 2022-2025 | Prolate, Tanlor, Nalocet |
| Biotronik Nro, INC. | $79.54 | 2024-2025 | Prospera |
| Spr Therapeutics, INC | $63.73 | 2024 | Sprint Pns System |
| Valinor Pharma, LLC | $52.94 | 2025 | Movantik |
| Hikma Pharmaceuticals USA | $52.28 | 2022 | |
| Merz Pharmaceuticals, LLC | $48.11 | 2022 | |
| Uswm, LLC | $47.59 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $46.08 | 2025 | |
| Fidia Pharma USA INC. | $39.35 | 2022-2024 | Hymovis, Triluron, Hyalgan |
| Averitas Pharma INC. | $34.77 | 2025 | Qutenza |
| Azurity Pharmaceuticals, INC. | $20.36 | 2024 | Horizant |
| Nevro Corp. | $20.30 | 2023 | Senza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $18.47 | 2024 | Xtampza |
| Baudax Bio INC. | $16.04 | 2022 | |
| Biodelivery Sciences International, INC. | $14.16 | 2021 | |
| Mml US, INC. | $11.22 | 2025 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salima Dewani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.